High-dose statin therapy reduced first, subsequent CV events

February 2010
Cardiology Today;Feb2010, Vol. 13 Issue 2, p10
The article discusses research on the association of intensive statin therapy with a reduction of subsequent cardiovascular events, with a reference to a study by M. J. Tikkanen that was published in an issue of the "Journal of the American College of Cardiology."


Related Articles

  • SCIENTIFIC COMMUNICATIONS. Kalmansohn, Robert B.; Kalmansohn, Richard W.; Schiff, David L. // Angiology;May2001, Vol. 52 Issue 5 

    Presents indications for statin therapy in United States. Effect of statin therapy on coronary artery disease; Performance of prevention trial; Need for an amendment of the National Cholesterol Education Program guidelines.

  • QOF set to get first statin primary prevention target.  // Pulse;6/9/2010, Vol. 70 Issue 20, p4 

    The article reports on the move of the independent quality and outcomes framework (QOF) indicator advisory committee to include the use of statins for primary prevention of cardiovascular disease in Great Britain.

  • GPs skewing statin prescribing away from at-risk groups. Gough, Rob // Pulse;10/14/2002, Vol. 62 Issue 39, p7 

    Reports on the results of the study on prescription of statins for cardiovascular diseases. Preference of statin prescription on low-risk patients by physicians; Source of blood lipid levels for patients prescribed with statins; Indications on the need for statins.

  • CHOOSE MAXIMAL STATIN MONOTHERAPY BEFORE UNPROVEN COMBINATION. Harkness, James R.; Blumenthal, Roger S. // Cardiology Today;Feb2012 Practical Lipidology, p15 

    The article focuses on clinical studies comparing the effectiveness of high-dose statin monotherapy and combination statin therapy in reducing cardiovascular disease risk.

  • If You're Already on a Statin, Does Adding Niacin Help? Kuritzky, Louis // Internal Medicine Alert;1/15/2012 Supplement, p7 

    The article discusses a study which found that the risk for cardiovascular events is not reduced by adding niacin to statins in persons with stable atherosclerotic vascular disease.

  • Individual Drugs.  // WHO Drug Information;2003, Vol. 17 Issue 3, p156 

    Discusses issues concerning drug safety and efficacy. Role of statins in primary prevention; Management of noncommunicable diseases; Strategy to reduce cardiovascular disease.

  • Statins decrease cardiovascular risks in diabetic patients.  // Geriatrics;Aug2003, Vol. 58 Issue 8, p46 

    Discusses the effectiveness of statins in decreasing cardiovascular risks in diabetic patients. Effects of simvastatin allocation on percentages of diabetics having major vascular events; Absence of negative effects in the areas of renal function, diabetes control, development of diabetes and...

  • CHOOSE STATIN COMBINATION THERAPY OVER HIGHER-DOSE STATIN. Miller, Michael // Cardiology Today;Feb2012 Practical Lipidology, p14 

    The article examines the clinical superiority of statin combination therapy over statin monotherapy to reduce cardiovascular disease (CVD) risk.

  • Inflammation in Cardiovascular Disease and Regulation of the Actin Cytoskeleton in Inflammatory Cells: The Actin Cytoskeleton as a Target. Thomas, T. H.; Advani, A. // Cardiovascular & Hematological Agents in Medicinal Chemistry;2006, Vol. 4 Issue 2, p165 

    Cardiovascular disease is prevalent in developed countries causing very large burdens to health services. The underlying pathology is atheromatous plaque in the sub-endothelial region of the vascular wall. High levels of low density lipoprotein cholesterol and high blood pressure cause...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics